Analyst coverage - Kolinpharma S.p.A

KOLINPHARMA

IT | EN | FR | ES | DE

La nostra Mission

Investor Relations
Documenti utili per gli investitori

Analyst coverage

dati aggiornati il 06/06/2023 alle 04:44

Anno 2023

Pubblicato il 12/04/2023 19:30	Equity Research FY 22 Update FY22: sales +26% YoY, consistent profitability, net cash at yearend
Pubblicato il 29/03/2023 20:02	Equity Research - UPDATE NOTE FY22 Continuous solid growth in FY22 (sales +26%), investments in internationalization for mid/long term growth

Anno 2022

Pubblicato il 26/10/2022 20:01	EQUITY RESEARCH - H1 22 Update H1 22 prescriptions growth outperforming the market, sales at €5.7m (+12% vs H1 21), profitability slowdown, access to Chinese market
Pubblicato il 06/10/2022 18:15	EQUITY RESEARCH - UPDATE NOTE 1H22 1H22: solid top-line growth, pressure on margins to be recovered in 2H
Pubblicato il 27/04/2022 18:35	EQUITY RESEARCH - FY21 Update FY21 Sales +36 YoY, sustained by MSRs’ growth
Pubblicato il 13/04/2022 23:31	Equity Research UPDATE NOTE FY21 FY2 results confirm future positive mid-term prospects

Anno 2021

Pubblicato il 18/10/2021 11:01	EQUITY RESEARCH - H1 2021 Update Remarkable sales along H1 2021 vs H1 2020 and vs H1 2019, revision of 2021 higher pre-Covid targets, continuing internationalization process and new targets for 2024
Pubblicato il 06/10/2021 09:05	IR Top Research Kolinpharma Update 1H21 Strong 1H21 results and new strategic plan
Pubblicato il 04/08/2021 09:27	EQUITY RESEARCH - Flash note August 3rd, 2021 H1 21 Sales €5.1m, +110% vs H1 20 and +65% vs H1 19
Pubblicato il 29/04/2021 10:26	ENVENT EQUITY RESEARCH - FY20 Update April 28th, 2021 Catching up previous growth path, reassuring outlook
Pubblicato il 13/04/2021 19:30	IR TOP Research - Kolinpharma FY 20 Update 13 04 2021 Strong recovery in 2H20, profitability above expectations

Anno 2020

Pubblicato il 17/10/2020 06:18	ENVENT EQUITY RESEARCH - FY19 Update October 16th, 2020 Slowdown, working to re-enter growth track
Pubblicato il 14/10/2020 18:00	IR TOP Research - KOLINPHARMA REPORT 1H 20 RESULTS Investments in R&D and HR to drive future growth
Pubblicato il 02/05/2020 11:35	ENVENT EQUITY RESEARCH - FY19 Update April 30th, 2020 Delivery on IPO promises, reassuring outlook
Pubblicato il 28/04/2020 10:15	IR TOP Research - Kolinpharma FY 19 Update 27 04 2020 FY19: Revenue growth and cashflow above expectations

Anno 2019

Pubblicato il 22/10/2019 18:08	IR TOP Research - Update Report 1H 2019 Results A strong set of 1H 2019 results
Pubblicato il 22/10/2019 15:50	ENVENT EQUITY RESEARCH - H1 2019 Update October 21st, 2019 Revenues and operating margins up in H1 2019, patents in the USA add value perception
Pubblicato il 17/04/2019 22:18	IRTOP FY 2018 Results – April 17th, 2019 6:00 p.m. Strong FY 2018 results and new business plan
Pubblicato il 17/04/2019 22:23	ENVENT EQUITY RESEARCH - FY18 Update April 15th, 2018 A good start to 2019, with a new product launch coupled with rewarding FY18 accounts, led by near 80% revenue growth.

Anno 2018

Pubblicato il 16/10/2018 08:50	IR TOP Research - H1 2018 Update October 15, 2018 Company: IR Top Research; Target price: 8,92 Euro
Pubblicato il 12/10/2018 10:13	Equity Research EnVent - H1 2018 Update October 8, 2018 Company: EnVent Research & Analysis; Target price:8,33 Euro
Pubblicato il 23/04/2018 12:28	Equity Research EnVent - Initiation of Coverage KOLINPHARMA April 18, 2018 Company: EnVent Research & Analysis; Target price:8,54 Euro
Pubblicato il 05/04/2018 12:52	KOLINPHARMA - First Coverage IR Top Research April 4, 2018 Company: IR Top Research; Target price: 8,67 Euro

Investor Relations

Eventi e Investor day

Calendario eventi societari

Comunicati Stampa Finanziari

Assemblee degli azionisti

Bilanci e Relazioni

Analyst coverage

Info per gli Azionisti

Contatti investor relations

“Il rigore della scienza, l’ascolto delle persone”

“Il rigore della scienza, l’ascolto delle persone”